With diverse management experience in the life science industry and over 100 years of collective experience, our leadership team is ready to change the shape of medical research and practice.
Taylor J. Crouch, Chief Executive Officer and President
Mr. Crouch has over 25 years of experience building and leading technology, expertise and product-based companies in the life sciences and biotech industries. For more than seven years, he has managed and served as an operational investor in a group of leading clinical research site companies. Specifically, Mr. Crouch served as Chief Executive Officer at eStudySite, a position he held from January 2009 to June 2016; as Executive Chairman of Meridien Research from December 2013 to September 2016; and as a Director of the National Research Institute from September 2011 through July 2016. He was instrumental in building these three sister companies, and helping them to achieve significant and profitable growth and to become recognized leaders in their respective fields of infectious disease, CNS disorders and metabolic disease. Prior to this, Mr. Crouch served as Senior Vice President of Operations/President International at Ligand Pharmaceuticals from 2005 to 2007, with responsibilities for new business development, technical operations, international sales and clinical research. Prior to Ligand, he was President and Chief Operating Officer of Discovery Partners International (NASDAQ: formerly DPII – a large drug discovery services and technology provider). Earlier in his career, he was Chief Executive Officer of Variagenics (NASDAQ: formerly VGNX – a leading pharmacogenomics company), Senior Vice President of Marketing and Sales at Parexel – a global CRO, and he also held international management positions in new product development and commercialization at Pfizer and Schering Plough. Mr. Crouch holds a BSE in chemical engineering, cum laude, from Princeton University and an MBA in international marketing and finance from the University of Chicago.
Craig Kussman, Chief Financial Officer
Mr. Kussman has more than 20 years of financial and general management experience in the healthcare sector. He is an accomplished executive with extensive financial, strategic and operational experience in technology and biotechnology companies ranging from large public multinational corporations to private start-ups. Mr. Kussman spent the prior 2 years at ALPHAEON® Corporation as CFO, where he helped raise over $150 million in equity and debt capital, as well as complete five acquisitions to help the company scale rapidly. Prior to this role, Mr. Kussman served as CFO at XIFIN, Inc., where he helped lead XIFIN’s private equity recapitalization with GTCR. In addition, Mr. Kussman served as CFO and co-CEO at Breach Security, before successfully negotiating its sale to Trustwave, and as CFO and senior vice president of corporate development for Ascenta Therapeutics, a development stage biopharmaceutical company, leading the company’s $52 million Series C financing. Kussman has also held senior executive positions at Discovery Partners International, Inc., SYNAVANT Inc., Cognizant Corp., and IMS Health, in addition to various financial and corporate development positions at The Dun & Bradstreet Corporation. Kussman earned a B.A. cum laude in economics and mathematics from Pomona College and an M.B.A. with distinction in Finance from the Wharton School of Business at the University of Pennsylvania.
Sharon Collins Presnell, Ph.D., Chief Scientific Officer, Organovo & President, Samsara
Dr. Presnell has more than 18 years of experience leading product-focused R&D. As an assistant professor at the University of North Carolina at Chapel Hill, Dr. Presnell’s research in liver and prostate biology and carcinogenesis produced cell and tissue-based technologies that were outlicensed for industrial applications. She joined Becton Dickinson (BD) in 2001 and played a key role in the early discovery and development of BD’s Discovery Platform and FACSTM CAP tools for the optimization of in vitro culture environments and flow cytometry-based characterization of cells. In her role at BD, she grew and led a large multi-disciplinary team to establish feasibility for the Discovery Platform and FACS CAP in multiple therapeutic areas, including diabetes, and stewarded both technologies through revenue-generating commercial partnerships. Dr. Presnell joined Tengion, Inc. in 2007 as the Vice President of Regenerative Medicine Research and was responsible for the discovery and early development of Tengion’s Neo-Kidney Augment™ technology, which MedTronic secured first rights to purchase in a 2011 deal. Dr. Presnell holds a Ph.D. in pathology from the Medical College of Virginia.
Steven G. Hughes, Chief Medical Officer
Dr. Hughes has over 18 years of experience building and leading clinical development and medical affairs teams at leading biopharma companies. He has been involved in more than 50 clinical trials with more than 25 drugs across multiple therapeutic areas including cardiovascular, metabolic, neurology, oncology, infectious diseases, rheumatology, ophthalmology and rare diseases, in the U.S. and other regions. Dr. Hughes has also played a key role in the submission of three NDA/MAA applications. He most recently served as the Chief Clinical Development Officer at Ionis Pharmaceuticals, where he led a team that managed the global clinical development of 25 drugs across 10 therapeutic areas. Previously, he held positions as Global Medical Lead, Oncology Clinical Development and Medical Director, UK & Ireland at Biogen Idec. Dr. Hughes also held numerous senior clinical development, medical affairs and leadership positions of increasing responsibility at CSL Behring and Sanofi. Dr. Hughes is board certified in Pharmaceutical Medicine and received his medical degree from Imperial College, London. He also has an MBA with distinction from Imperial College Business School.
Jennifer Kinsbruner Bush, J.D., General Counsel, Corporate Secretary and Compliance Officer
Ms. Bush has more than 15 years of intellectual property, corporate legal, regulatory, compliance, and transactional experience. Prior to joining Organovo, Ms. Bush held positions of increasing responsibility at Broadcom Corp., where she was most recently Associate General Counsel. Before joining Broadcom, Ms. Bush served as Associate General Counsel of DivX, Inc. prior to its acquisition by Sonic Solutions in October 2010. Earlier in her career, Ms. Bush was a Principal at Fish & Richardson, from 2001 to January 2010, where she represented clients focused on a variety of technologies, including in the areas of medical devices, life sciences, software, and consumer products. Ms. Bush received a J.D. from Yale Law School and an A.B. in history and Latin American studies from Princeton University.
Paul Gallant, General Manager
Mr. Gallant has more than 20 years of management and R&D experience in the drug discovery industry, most recently serving as chief operating officer for DiscoveRx, a global scientific product and services company. As Chief Operating Officer at DiscoveRx, Mr. Gallant was responsible for the company’s largest business unit, drug discovery services. Mr. Gallant formerly served as senior director at Ambit Pharmaceuticals, acquired by DiscoveRx in 2010, where he led the development and commercialization for the KINOMEscan platform. The world’s largest commercial kinase screening panel, KINOMEscan became a key element of DiscoveRx’s offering post-acquisition. Mr. Gallant has also led R&D and service teams at Amgen, Millennium Pharmaceuticals, Cubist Pharmaceuticals and Massachusetts General Hospital. He earned a B.A. in biology from Colby College.